.
Prostaglandin E 2 (PGE 2 ) is formed from PGH 2 by enzymes known as PGE synthases. Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible enzyme expressed in various human cell types (1) whereas the two other PGE 2 synthases, microsomal prostaglandin E synthase-2 (mPGES-2) and cytosolic prostaglandin E synthase (cPGES), are constitutively expressed and presumed to have a physiological role. mPGES-1, as well as COX-2 enzyme, is induced by inflammatory cytokines such as interleukin-1β (IL-1β), lipopolysaccharide (LPS) and tumour necrosis factor-α (TNF-α) (2,3). COX-2 and mPGES-1 are both overexpressed in connection with pathological processes including inflammation.
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit both of the COX enzymes suppressing the formation of PGH 2 and all of its terminal products including PGE 2 . Inhibition of PGE 2 synthesis is regarded as the main mechanism of the therapeutic effects of NSAIDS. Unfortunately, the most common adverse effects of NSAIDs also appear to be mediated through reduced prostanoid production. Especially the cardiovascular side effects now known to be associated with the use of both non-selective and COX-2 selective NSAIDs are mediated through inhibition of the synthesis of prostanoids other than PGE 2 (3) (4) (5) . A specific mPGES-1 inhibitor is therefore hypothesized to retain the therapeutic activity of NSAIDs with less adverse effects (5, 6) .
In addition to its physiological roles, PGE 2 is a vital mediator of inflammatory responses, pain and fever playing an important role in the mechanisms and symptoms of rheumatic diseases. mPGES-1 levels have previously been shown to be high in the synovial cells from patients with rheumatoid arthritis (RA) (7) and osteoarthritis (OA) (8) . A convincing evidence of its pathophysiological role is also presented in an experimental model of RA in mPGES-1 knockout mice where the incidence and severity of the disease, its clinical score and joint damage were reduced in knockout mice as compared to wild type controls (9) . This suggests that inhibition of the pathological increase of mPGES-1 levels during arthritis might suppress the inflammatory activity and prevent / retard the progression of joint erosions.
The aim of the present study was to investigate the expression of mPGES-1 in activated primary human chondrocytes, and to study the effects of DMARDs methotrexate, sulfasalazine aurothiomalate and hydroxychloroquine, and of glucocorticoid dexamethasone on it.
MATERIALS AND METHODS
The study was approved by the Ethics Committee of Tampere University Hospital, Tampere,
Finland and a written informed consent was obtained from the patients. Leftover pieces of OA cartilage from knee joint replacement surgery were received from Coxa Hospital for Joint Replacement, Tampere, Finland and processed as earlier described (10).
Isolated chondrocytes were plated at the density of 0.15 milj/ml in 24-well plates in DMEM culture medium with GIBCO GlutaMAX-I supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml) and amphotericin B (250 ng/ml) containing 10% fetal bovine serum, and cultured at 37°C in a humidified 5% carbon dioxide atmosphere. After 24h incubation, the cells were treated with the compounds of interest. RNA or proteins were extracted and cell culture media collected after the desired time of incubation. RNA extraction and real-time RT-PCR, preparation of cell lysates for
Western blot, and Western blot analysis were carried out as previously described (11).
Primer and probe sequences for human mPGES-1 were CACGCTGCTGGTCATCAAGA (forward), CCGTGTCTCAGGGCATCCT (reverse) and AGCCTCACTTGGCCCGTGATG (probe).
Antibodies used in Western blot analysis were rabbit polyclonal antibody for mPGES-1 (AS-03031, Agrisera AB, Vännäs, Sweden; primary antibody) and goat anti-rabbit RESULTS mPGES-1 expression in unstimulated chondrocytes was low and a clear increase in its expression levels were found when IL-1β was introduced into the culture (Fig. 2) . mPGES-1 mRNA expression increased up to 48 h and declined thereafter ( Fig. 2A) whereas the protein expression continued to increase throughout the 96 h follow-up (Fig. 2B ). As seen in Figure 2 , the mPGES-1 expression in IL-1β -activated primary chondrocytes demonstrated relatively slow onset and long duration.
The effects of dexamethasone, aurothiomalate, sulfasalazine, methotrexate and hydroxychloroquine on IL-1ß -induced mPGES-1 expression were investigated. Aurothiomalate and dexamethasone significantly down-regulated mPGES-1 expression whereas sulfasalazine, methotrexate and hydroxychloroquine had no effect (Fig 3A) . The effect of aurothiomalate on mPGES-1 mRNA expression was dose-dependent ( Fig. 3B) and it was reflected as reduced mPGES-1 protein levels ( Fig. 3C ) and PGE 2 production (Fig. 3D) .
DISCUSSION
In the present study, we measured the expression of mPGES-1 in primary human chondrocytes, and investigated the effects of DMARDs aurothiomalate, sulfasalazine, methotrexate and hydroxychloroquine, and dexamethasone on it. Interestingly, aurothiomalate was found to inhibit the expression of mPGES-1 which is an original finding. The other DMARDs studied did not effect mPGES-1 expression while dexamethasone reduced mPGES-1 levels and PGE 2 production. The effects of aurothiomalate on mPGES-1 expression and PGE 2 production were dose-dependent, and a significant inhibition was achieved at clinically relevant concentration of 25 µM which can be maintained in serum during intramuscular aurothiomalate treatment (12) . Further, aurothiomalate levels in synovial fluid are reported to correspond the serum levels during drug treatment (13) .
It has previously been reported that glucocorticoids inhibit the expression of both mPGES-1 and COX-2 enzymes (2) and therefore dexamethasone was selected as a control compound when we evaluated the effects of disease-modifying antirheumatic drugs (DMARD) on the expression of mPGES-1. Methotrexate, sulfasalazine and hydroxychloroquine (triple therapy) were selected to this design because using them with a small dose of glucocorticoid as a combination therapy is evidently more effective treatment in RA than using a single DMARD with or without a small daily dose of glucocorticoid (14) . The above mentioned combination is also recommended in the A selective inhibition of PGE 2 formation might be an effective manner to treat many types of pain with less adverse effects as compared to NSAIDs. Intensive research on mPGES-1 inhibitors has been ongoing since the enzyme was characterized, and many compounds with different molecular structures seem to inhibit it, but a specific inhibitor appliable for clinical use is yet to be discovered (5, (21) (22) (23) (24) . Another approach to reduce PGE 2 production especially in inflammatory conditions might be down-regulation of mPGES-1 expression and according to the present findings that is achieved by using aurothiomalate but not with the other commonly used DMARDs.
In conclusion, the results of the present study introduce aurothiomalate as the first and so far the only DMARD found to be able to inhibit mPGES-1 expression. The effect is likely involved in the mechanisms of action for this gold containing DMARD in rheumatic diseases. These results are implicated in the regulatory mechanisms of mPGES-1 that are under intensive research to develop improved treatments for inflammation and inflammatory pain. A: Cells were incubated with IL-1β (100 pg/ml) and RNA was extracted at indicated time-points.
FIGURE LEGENDS
mPGES-1 mRNA levels were analyzed with quantitative real-time reverse transcriptionpolymerase chain reaction (RT-PCR) and normalized against GAPDH. Untreated cells were used as control, and expression levels were quantified against them.
B: Cells were incubated with IL-1β (100 pg/ml) and proteins were extracted at indicated time-points.
Untreated cells were used as control, and mPGES-1 expression levels determined by Western blotting were quantified against them. Actin was used as a loading control.
Values are mean + SEM expressed as fold increase from baseline (considered as 1) in arbitrary units, n=4-6, ** = p < 0.01. A and B: Cells were treated with IL-1β (100 pg/ml) and the compounds of interest for 48 h and RNA was extracted thereafter, subjected to RT-PCR and normalized against GAPDH. Untreated 
